A 18-year-old girl with amenorrhea for 2 years, galactorrhea, and progressive weight loss (from 63 to 45 kg) visited the hospital. Brain magnetic resonance imaging (MRI) was conducted for the evaluation of amenorrhea, and results revealed a 6.3 cm multiloculated cystic and solid enhancing mass involving the right basal ganglia, right hypothalamus, pituitary stalk, pituitary gland, 3
rd ventricle, right anterior thalamus, and right frontal lobe and a 1.1 cm additional enhancing mass in the pineal gland, indicating off-midline and pineal germinoma (
Fig. 1). She presented with polyuria, and her laboratory examination results were as follows: sodium (Na) level, 159 mEq/L; plasma osmolality, 323 mOsm/kg; urine specific gravity, ≤1.005; urine osmolality, 216 mOsm/kg. Moreover, the patient complained of thirst. The anterior pituitary hormonal profile showed low free T4 (0.546 [range 0.7–1.8] ng/dL), normal serum TSH (2.12 [range 0.2–4.2] ng/dL), low cortisol (3.6 [range 8–19] µg/dL), normal serum adrenocorticotropic hormone (34 [range 10–60] pg/mL), pre-pubertal gonadotropin (LH level: <0.01 mIU/mL, FSH level: 0.61 mIU/mL) and elevated serum prolactin levels (41.3 [range 4.8–23.3] ng/mL). The patient was diagnosed with CDI and panhypopituitarism and was treated with l-thyroxine, hydrocortisone, and desmopressin, and replacement therapy was begun 5 days before surgery. Fifteen hours after surgery, the patient presented with increased urine output, from a diuresis of 700 cc over 6 h to 1,900 cc over 4 h (9 cc/kg/h). Thus the patient was treated with 200 mg of hydrocortisone for 24 h, and a total of 3,300 cc of intravenous plasma solution was administered within 24 h. During this time, the patient’s Na level increased from 148 to 153 mEq/L. The patient was considered as inadequately controlled CDI; thus, a part from oral desmopressin, 15 U of vasopressin was administered subcutaneously. On the second postoperative day, the patient presented with diuresis of 5,000 cc over 24 h (4.7 cc/kg/h). Thus, she received treatment with desmopressin, 200mg of hydrocortisone for 24 h, as well as 1,200 cc of intravenous fluids and 2,500 cc of oral fluids. The patient presented with hypernatremia, with a Na level at 147 mEq/L. After several days, the Na levels normalized, and intravenous isotonic saline infusion was continually administered. On day 8, the patient underwent 1
st chemotherapy for 3 days. Massive vomiting occurred, and the clinical symptoms of dehydration persisted. Although the dose of desmopressin was increased, she still presented with polyuria (7,210 cc, 6.0 cc/kg/h) with a decrease in Na level from 148 to 125 mEq/L on day 13. Hypernatremia improved after increasing the intravenous hypertonic fluid rate and hydrocortisone dose. Furthermore, the dose of oral desmopressin was increased up to 0.8 mg per day with nasal desmopressin as needed. Two months after surgery, the patient received routine pre-chemotherapy hydration that is twice her maintenance rate and started 3
rd chemotherapy (intravenous carboplatin, 450 mg/m
2 for 1 day, etoposide 150 mg/m
2 for 3 days). The patient presented with nausea and polyuria with slight dehydration. Ongoing treatment was required with high amounts of intravenous sodium supplementation. However, her serum Na level continually decreased below 135 mEq/L with high urinary losses (urine Na level: 34–201 mEq/L). With symptoms, such as polyuria and hyponatremia, the diagnosis of CDI combined with CSWS was considered. A plasma aldosterone level <14.8 (range: 30–160) pg/mL and renin activity at 0.06 [range: 0.32–1.84 (supine)] ng/mL per hour were suppressed. Attempts at weaning the concentration and rate of hypertonic saline replacement were thwarted by hyponatremia and polyuria of up to 7 L per day (6.9 mL/kg/h). Fludrocortisone (0.05 mg daily) treatment was initiated because it is effective as an adjunct treatment for CSWS. However, the patient still presented with hyponatremia, polyuria and natriuresis after the 4
th chemotherapy period. Despite the initiation of fludrocortisone, the patients’ serum sodium level was 128 mmol/L; urine output, was 5.5 mL/kg per h; and urine sodium level, 38 mEql/L. She presented a hyponatremic seizure which was treated with hypertonic saline (characterized by generalized tonic movement, 3 times a day, lasting about 2 to 3 minutes). In addition, the dose of fludrocortisone was gradually increased to a maximum of 0.3 mg daily. Shortly thereafter, the serum Na level improved (145 mEq/L), and the urinary Na level decreased (
Table 1). Her urinary volume subsequently normalized (4 mL/kg/h). The hypertonic fluid dose was gradually decreased. She was discharged from the hospital 19 days after the initiation of fludrocortisone and was treated with fludrocortisone 0.3 mg a day, orally desmopressin 0.8 mg/day, hydrocortisone 25 mg/day, and levothyroxine 50 mcg/day. Treatment with fludrocortisone was continued at a dose of 0.3 mg daily for another 5 months and was then decreased. Sixteen months after surgery, the patient still required oral desmopressin (0.5 mg/day) and fludrocortisone 0.1 mg per day along, with corticosteroids and, levothyroxine (50 mcg/day). Thus, the electrolyte level of the patient was maintained at normal. Follow-up brain MRI revealed that the germinoma had a stable status for 16 months.